MedTrace Logo

A Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03691831 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 502

Last updated 2020-10-27

Study results available
· View outcomes & findings →

Summary

Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts

Conditions

  • Common Wart

Interventions

DRUG

Active

A-101 45% (hydrogen peroxide 45% topical solution)

OTHER

Vehicle

Vehicle solution containing isopropyl alcohol and water

Sponsors & Collaborators

  • Aclaris Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Judy Schynder · Aclaris Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-13
Primary Completion
2019-04-21
Completion
2019-07-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03691831 on ClinicalTrials.gov